CytomX Therapeutics Q4 2024: Contradictions in CX-2051 and CX-904 Development Plans
Thursday, Mar 6, 2025 9:38 pm ET
1min read These are the key contradictions discussed in CytomX Therapeutics' latest 2024 Q4 earnings call, specifically including: CX-2051's dose escalation and patient selection, CX-904's trial collaboration and data presentation timeline, CX-2051 dose escalation expectations, and CRC focus for EpCAM ADC:
Clinical Pipeline Progress:
- CytomX's lead program, CX-2051, progressed into phase I clinical trials in Q2 2024, targeting colorectal cancer.
- The company expects initial Phase Ia data in CRC by the first half of 2025, with potential RECIST responses in a late-line patient population.
- This advancement is aimed at addressing a large unmet need in CRC, where current treatments have limited efficacy.
Cash Runway Extension:
- CytomX extended its cash runway to the second quarter of 2026 through strategic prioritization, achieving cash guidance without additional milestones.
- As of December 31, 2024, CytomX ended the year with $100.6 million in cash, compared to $174.5 million in 2023.
- This extension supports CytomX's ability to deliver on key clinical milestones.
Revenue and Collaborations:
- CytomX reported total revenue of $138.1 million in 2024, up from $101.2 million in 2023, driven by collaborations with BMS, Moderna, Astellas, and Regeneron.
- The increase was attributed to the progress and milestones achieved in various research and development partnerships.
Research and Development Focus:
- Research and development expenses increased by $5.7 million to $83.4 million in 2024, mainly due to a $5 million milestone payment for CX-2051's Phase I start.
- This increase reflects CytomX's commitment to advancing its clinical pipeline and partner collaborations.
Clinical Pipeline Progress:
- CytomX's lead program, CX-2051, progressed into phase I clinical trials in Q2 2024, targeting colorectal cancer.
- The company expects initial Phase Ia data in CRC by the first half of 2025, with potential RECIST responses in a late-line patient population.
- This advancement is aimed at addressing a large unmet need in CRC, where current treatments have limited efficacy.
Cash Runway Extension:
- CytomX extended its cash runway to the second quarter of 2026 through strategic prioritization, achieving cash guidance without additional milestones.
- As of December 31, 2024, CytomX ended the year with $100.6 million in cash, compared to $174.5 million in 2023.
- This extension supports CytomX's ability to deliver on key clinical milestones.
Revenue and Collaborations:
- CytomX reported total revenue of $138.1 million in 2024, up from $101.2 million in 2023, driven by collaborations with BMS, Moderna, Astellas, and Regeneron.
- The increase was attributed to the progress and milestones achieved in various research and development partnerships.
Research and Development Focus:
- Research and development expenses increased by $5.7 million to $83.4 million in 2024, mainly due to a $5 million milestone payment for CX-2051's Phase I start.
- This increase reflects CytomX's commitment to advancing its clinical pipeline and partner collaborations.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.